Hemostemix Inc.

About Hemostemix Inc.

Hemostemix is a biotechnology company focused on developing safe and effective autologous stem cell therapies to transform lives and provide new treatment options and hope for millions of patients globally. Their mission involves creating innovative treatment protocols for various medical conditions using the patient's own cells.

Products & Services

ACP-01:An investigational autologous stem cell therapy designed to generate new blood vessels and restore oxygen and nutrient flow to areas damaged by ischemia. It has been studied in clinical trials for conditions like Angina, Ischemic and Dilated Cardiomyopathy, Peripheral Arterial Disease (PAD), and Chronic Limb Threatening Ischemia (CLI).

Specialties

Autologous Stem Cell Therapies Angiogenic Precursor Cell Treatment Treatment of Critical Limb Ischemia Cardiomyopathy Treatment Peripheral Arterial Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-Brokered Private Placement T: - FT: Non-Brokered Private Placement	A: 1800000 MR: - FA: $1,800,000 FAN: 1800000	D: 2024-06-03 FD: 2024-06-03	-
2	RT: Private Placement T: - FT: Private Placement	A: 403540 MR: - FA: $403,539.96 FAN: 403540	D: 2023-06-28 FD: 2023-06-28	-
3	RT: Private Placement T: - FT: Private Placement	A: 1200000 MR: - FA: up to $1,200,000 FAN: 1200000	D: 2023-06-21 FD: 2023-06-21	-
4	RT: Private Placement T: - FT: Private Placement	A: 762400 MR: - FA: 762,400 FAN: 762400	D: 2023-03-21 FD: 2023-03-21	-
5	RT: Unit Offering T: - FT: Unit Offering	A: 2800000 MR: - FA: 14 Million Common Share Units at $0.20 each FAN: 2800000	D: 2023-03-08 FD: 2023-03-08	-
6	RT: Convertible Debenture T: - FT: Convertible Debenture	A: 17500000 MR: - FA: up to $17,500,000 FAN: 17500000	D: 2023-03-07 FD: 2023-03-07	-
7	RT: Private Placement T: - FT: Private Placement	A: 3360000 MR: - FA: Up to 14,000,000 units at $0.24 each FAN: 3360000	D: 2023-02-01 FD: 2023-02-01	-
8	RT: Grant T: - FT: Grant	A: 250000 MR: - FA: $250,000 FAN: 250000	D: 2023-01-23 FD: 2023-01-23	1 investors
9	RT: Non-Dilutive T: - FT: Non-Dilutive	A: 250000 MR: - FA: $250,000 FAN: 250000	D: 2023-01-19 FD: 2023-01-19	1 investors

Non-Brokered Private Placement Latest

2024-06-03

$1.8M

Private Placement 2023-06-28

$404K

Private Placement 2023-06-21

$1.2M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas A. Smeenk

President & CEO, Co-Founder

F

Fraser C. Henderson Sr.

Chief Medical Officer

M

Mary Argent-Katwala

Manager, Clinical Trials

P

Peter Lacey

Chairman of the Board

R

Ronnie Hershman

Director

L

Loran Swanberg

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Hemostemix Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised